Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: A double-blind placebo-controlled study

Cardiovascular Diabetology

Volumn 2, Issue , 2003, Pages

  Rosano, Giuseppe M C ^a   Vitale, Christiana ^a   Sposato, Barbara ^a   Mercuro, Giuseppe ^a   Fini, Massimo ^a  

^a Cardiovascular Research Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PLACEBO; TICLOPIDINE; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; GLUCOSE UTILIZATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MOVEMENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 2942512039     PISSN: 14752840     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2840-2-16     Document Type: Article

References (22)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
2. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ et al.: Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996, 28:1661-1669.
3. Barzilay JI, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED: Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > or = 65 years (report from the Coronary Artery Surgery Study [CASS] Registry). Am J Cardiol 1994, 74:334-339.
4. McClellan KJ, Plosker GL: Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs 1999, 58:143-157.
5. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ: The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 1996, 17:96-103.
6. Savonitto S, Ardissiono D, Egstrup K, Rasmussen K, Bae EA, Omland T, Schjelderup-Mathiesen PM, Marraccini P, Wahlqvist I, Merlini PA et al.: Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996, 27:311-316.
7. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A: Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 1990, l4:853-859.
8. Thadani U: Management of patients with chronic stable angina at low risk for serious cardiac events. Am J Cardiol 1997, 79:24-30.
9. Jackson G: Haemodynamic and metabolic agents in the treatment of stable angina: publication review. Coron Artery Dis 2001, 12:S22-24.
10. Manchanda SC, Krishnaswami S: Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997, 78:353-357.
11. Desideri A: An overview of trimetazidine: Clinical studies in coronary artery disease. Res Clin Forums 1995, 17:43-51.
12. Lu C, Dabrowski P, Fragasso G, Chierchia SL: Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998, 82:898-901.
13. American Diabetes Association Clinical Practice Recommendations 2001. Diabetes Care 2001, 24:S1-133.
14. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of echocardiography Nomenclature and Standards Committee and task force for a standard Echocardiography report. J Am Soc echocardiogr 2002, 15:275-290.
15. Kantor PF, Lucien A, Kozak R, Lopaschuk GD: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000, 86:568-580.
16. Lopaschuk GD: Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001, 12:S8-11.
17. Belardinelli R, Purcaro A: Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001, 22:2164-2170.
18. Pogatsa G: Metabolic energy metabolism in diabetes: therapeutic implications. Coron Artery Dis 2001, 12:S29-33.
19. Mandinov L, Eberli FR, Seiler C, Hess OM: Diastolic heart failure. Cardiovasc Res 2000, 45:813-25.
20. Zile MR, Brutsaert DL: New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part II Causal Mechanisms and Treatment. Circulation 2002, 105:1503-1508.
21. Bonow RO: The hibernating myocardium: implications for management of congestive heart failure. Am J Cardiol 1995, 75:17A-25A.
22. Szwed H, Sadowski Z, Pachocki R, Domzal-Bochenska M, Szymczak K, Szydlowski Z, Paradowski A, Gajos G, Kaluza G, Kulon I et al.: The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther 1999, 3:217-222.